• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.

作者信息

Constantine Gregory M, Bressler Peter B, Petroni Daniel, Metcalfe Dean D, Carter Melody C

机构信息

The National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Allergic Disease, Bethesda, Md.

Professional Association, Duke University, Durham, NC.

出版信息

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1314-1316. doi: 10.1016/j.jaip.2018.07.041. Epub 2018 Aug 24.

DOI:10.1016/j.jaip.2018.07.041
PMID:30149096
Abstract
摘要

相似文献

1
Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.2例系统性肥大细胞增多症患者接受奥马珠单抗治疗过敏性反应的12年随访
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1314-1316. doi: 10.1016/j.jaip.2018.07.041. Epub 2018 Aug 24.
2
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.奥马珠单抗用于治疗系统性肥大细胞增多症患者的不明原因过敏反应。
J Allergy Clin Immunol. 2007 Jun;119(6):1550-1. doi: 10.1016/j.jaci.2007.03.032. Epub 2007 May 3.
3
Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.奥马珠单抗预防全身性肥大细胞增多症的过敏反应和改善症状：疗效和安全性观察。
Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27.
4
Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.奥马珠单抗使一名患有惰性系统性肥大细胞增多症的患者的特发性过敏反应得到缓解。
Acta Derm Venereol. 2014 May;94(3):363-4. doi: 10.2340/00015555-1687.
5
Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).奥马珠单抗治疗肥大细胞增多症的疗效：来自前瞻性、双盲、多中心研究（XOLMA 研究）的暗示性结果。
Dermatology. 2020;236(6):529-539. doi: 10.1159/000504842. Epub 2020 Jan 20.
6
Clinical response to omalizumab in patients with hereditary α-tryptasemia.遗传性α-色氨酸血症患者对奥马珠单抗的临床反应。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):99-100.e1. doi: 10.1016/j.anai.2019.09.026. Epub 2019 Oct 9.
7
Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis.遗传性α-胰蛋白酶血症在 101 例伴有过敏症状的肥大细胞激活相关症状的患者中发现，包括过敏反应。
Ann Allergy Asthma Immunol. 2021 Jun;126(6):655-660. doi: 10.1016/j.anai.2021.01.016. Epub 2021 Jan 17.
8
Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab.奥马珠单抗预防特发性过敏反应的过敏反应发作。
Int Arch Allergy Immunol. 2024;185(8):761-766. doi: 10.1159/000538046. Epub 2024 Mar 25.
9
Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.因孕酮超敏反应导致的过敏反应经奥马珠单抗成功治疗。
J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):852-854. doi: 10.1016/j.jaip.2017.01.003. Epub 2017 Mar 1.
10
Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).奥马珠单抗治疗难治性系统性和皮肤肥大细胞增多症的随机对照试验（ROAM）。
J Allergy Clin Immunol Pract. 2023 Jul;11(7):2248-2250.e3. doi: 10.1016/j.jaip.2023.04.008. Epub 2023 Apr 23.

引用本文的文献

1
Case report: The devil was hidden in the mastocytes - an unusually fulminant case of indolent systemic mastocytosis in a 45-year-old patient, missed for almost 20 years.病例报告：“恶魔潜伏在肥大细胞中”——一位 45 岁患者的惰性系统性肥大细胞增多症罕见暴发性病例，近 20 年来一直被漏诊。
Front Immunol. 2023 Feb 10;14:1134587. doi: 10.3389/fimmu.2023.1134587. eCollection 2023.
2
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.奥马珠单抗成功治疗系统性肥大细胞增多症患儿：临床和生物学意义。
Ital J Pediatr. 2023 Jan 13;49(1):6. doi: 10.1186/s13052-022-01402-7.
3

本文引用的文献

1
Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.奥马珠单抗预防全身性肥大细胞增多症的过敏反应和改善症状：疗效和安全性观察。
Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27.
2
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.肥大细胞增多症：2016年世界卫生组织更新分类及新出现的治疗理念。
Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28.
3
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper.
Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
肥大细胞活化综合征：国际变态反应学会 2022 年更新。
Int Arch Allergy Immunol. 2022;183(7):693-705. doi: 10.1159/000524532. Epub 2022 May 23.
4
Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.肥大细胞增多症和肥大细胞激活障碍：澄清问题。
Int J Mol Sci. 2021 Oct 19;22(20):11270. doi: 10.3390/ijms222011270.
5
Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.儿童肥大细胞增生症的分子背景、临床特征和治疗管理：2021 年现状。
Int J Mol Sci. 2021 Mar 4;22(5):2586. doi: 10.3390/ijms22052586.
6
Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis.肥大细胞增多症患儿的介质相关症状和过敏反应。
Int J Mol Sci. 2021 Mar 7;22(5):2684. doi: 10.3390/ijms22052684.
7
Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.奥马珠单抗对惰性系统性肥大细胞增多症的长期成功治疗
Fed Pract. 2021 Jan;38(1):44-48. doi: 10.12788/fp.0081.
8
FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.FcεRI-HDAC3-MCP1 信号轴通过细胞间相互作用促进被动过敏反应。
Int J Mol Sci. 2019 Oct 8;20(19):4964. doi: 10.3390/ijms20194964.
克隆性肥大细胞疾病中的药物超敏反应：ENDA/EAACI 立场文件。
Allergy. 2015 Jul;70(7):755-63. doi: 10.1111/all.12617. Epub 2015 Apr 24.
4
Epidemiology, prognosis, and risk factors in mastocytosis.肥大细胞增多症的流行病学、预后和危险因素。
Immunol Allergy Clin North Am. 2014 May;34(2):283-95. doi: 10.1016/j.iac.2014.01.003.
5
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.系统性肥大细胞增多症患者的严重危及生命或致残性过敏反应：单中心经验。
Int Arch Allergy Immunol. 2012;157(4):399-405. doi: 10.1159/000329218. Epub 2011 Nov 25.
6
Omalizumab in idiopathic anaphylaxis.奥马珠单抗治疗特发性过敏反应
Ann Allergy Asthma Immunol. 2009 Mar;102(3):257-8. doi: 10.1016/S1081-1206(10)60091-9.
7
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.肥大细胞增多症患者的过敏反应：120例患者的病史、临床特征及危险因素研究
Allergy. 2008 Feb;63(2):226-32. doi: 10.1111/j.1398-9995.2007.01569.x.
8
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.伴有嗜酸性粒细胞增多的KIT D816V相关系统性肥大细胞增多症和FIP1L1/PDGFRA相关慢性嗜酸性粒细胞白血病是不同的疾病实体。
J Allergy Clin Immunol. 2007 Sep;120(3):680-7. doi: 10.1016/j.jaci.2007.05.024. Epub 2007 Jul 12.
9
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.奥马珠单抗用于治疗系统性肥大细胞增多症患者的不明原因过敏反应。
J Allergy Clin Immunol. 2007 Jun;119(6):1550-1. doi: 10.1016/j.jaci.2007.03.032. Epub 2007 May 3.